Home/Hedge Fund Intelligence/Deep Track Biotechnology Master Fund
Hedge FundCayman IslandsMaster fund3(c)(7) · qualified purchasers

Deep Track Biotechnology Master Fund

Estimated returns, assets and SEC record

Managed by Deep Track Capital, LP · Greenwich · in Form ADV since 2021

Deep Track Biotechnology Master Fund is a Cayman Islands hedge fund managed by Deep Track Capital, LP. It reported gross assets of USD 5.1bn in the Form ADV filed 28 March 2024. Hedge funds do not file their returns with the SEC. From what this fund and its manager do file, PPLI Vortex estimates that it returned about 48.4% in 2025, with a likely range of 19.0% to 77.7%.

Unqualified audit opinionIndependent administratorPCAOB-registered auditor
2025, estimated+48.4%range 19.0% to 77.7% · grade D-13F · estimated for the manager as a whole
Three years, a year+20.7%2023 to 2025, compounded from the yearly estimates and their ranges
Latest quarter+15.7%to 30 Jun 2026 · range 4.1% to 27.4%
Gross assetsUSD 5.1bnForm ADV · filed 28 Mar 2024
Minimum investmentUSD 5mForm ADV, Schedule D
Investors134beneficial owners

Compiled by PPLI Vortex from SEC filings · Hedge Fund Intelligence, PPLI.com · updated · about PPLI Vortex

Return figures are PPLI.com estimates from public SEC filings, not numbers reported by the fund. Not investment advice. Important information

PPLI.com
Hedge Fund Rating
Rating in preparation
We publish a rating only once a fund's file has been through editorial review. This fund is in the queue.
Returns
Risk
SEC record and governance
Fees and terms
Fit for a PPLI policy
Editorial assessment from SEC filings
Reviewed every quarter
About the rating
D
Confidence grade D-13F

We rebuild the manager's long positions from Form 13F and scale them to how hedge funds of this kind have behaved. Shorts, leverage and fees are not visible.

How the grades work

A and B are computed from public filings. C, C-est and D-est are estimates built on what registered funds that hold the fund report. D-13F is an estimate from the manager's 13F long book. Every figure on this page is shown with its range and grade.

Quarter by quarter

Deep Track Biotechnology Master Fund, one quarter at a time

How the estimate moved through each year since 2021, with the yearly figure alongside.

Each cell is our estimate for that quarter, with the range it could fall in underneath. The last column is the figure for the full year. It is worked out on its own from the year's filings, so the four quarters will not multiply out to it exactly. Every figure here is graded D-13F. The quarters are estimated for the manager as a whole from its 13F long book and shown on each of its funds.

YearJan to MarApr to JunJul to SepOct to DecFull year
2026+0.9%-10.7% to 12.6%+15.7%4.1% to 27.4%not yet filednot yet filed+16.3%-6.9% to 39.6%, to 30 Jun
2025−5.0%-16.7% to 6.6%+4.3%-7.4% to 15.9%+19.3%7.6% to 30.9%+22.8%10.9% to 34.7%+48.4%19.0% to 77.7%
2024+5.5%-6.2% to 17.1%−1.1%-12.7% to 10.6%+4.2%-7.4% to 15.9%−1.7%-13.3% to 9.9%+10.3%-13.0% to 33.7%
2023−1.6%-13.3% to 10.0%+7.1%-4.5% to 18.8%−1.7%-13.4% to 9.9%+9.3%-2.3% to 21.0%+7.5%-15.9% to 30.8%
2022−4.9%-16.6% to 6.7%−7.9%-19.5% to 3.8%+11.6%-0.1% to 23.4%+8.3%-3.3% to 20.0%+4.5%-19.4% to 28.5%

Estimates by PPLI Vortex from public SEC filings, not figures reported by the fund. n/a means the filings do not support a figure for that quarter.

Next: what the manager holds
Holdings

67 positions, with 40% of the money in the ten largest

Deep Track Biotechnology Master Fund does not publish what it owns. Its manager does: every quarter Deep Track Capital, LP lists its U.S.-listed stocks and options on Form 13F. The list covers every account the firm runs, not this fund alone, and leaves out short positions, bonds, swaps and shares listed outside the United States. Most of what the firm's hedge funds hold is in this book, so it is a fair picture of the fund.

Value reportedUSD 6.9bn
Positions67
In the ten largest40%
Largest positionGuardant Health, Inc., 7.4%
Call options, underlying valueUSD 1
Holdings as of30 June 2026
The 15 largest positions

Share is of the total value reported. Options are shown at the value of the shares they cover. Choose a company to see which other managers report it.

#CompanyValueShare of the book
1 Nasdaq: GHHeld by 66 of the 720 managers we trackUSD 509m7.4%
2 Nasdaq: IMVTHeld by 28 of the 720 managers we trackUSD 360m5.2%
3 Nasdaq: GPCRADSHeld by 38 of the 720 managers we trackUSD 254m3.7%
4 Nasdaq: PCVXHeld by 34 of the 720 managers we trackUSD 250m3.6%
5 Nasdaq: ALNYHeld by 44 of the 720 managers we trackUSD 248m3.6%
6 NYSE: MANEStockHeld by 26 of the 720 managers we trackUSD 246m3.6%
7 Nasdaq: TARSHeld by 34 of the 720 managers we trackUSD 231m3.4%
8 NUVLHeld by 47 of the 720 managers we trackUSD 220m3.2%
9 Nasdaq: ALKSHeld by 39 of the 720 managers we trackUSD 210m3.1%
10 Nasdaq: OCULHeld by 36 of the 720 managers we trackUSD 193m2.8%
11 Nasdaq: BMRNHeld by 45 of the 720 managers we trackUSD 189m2.8%
12 Nasdaq: NRIXHeld by 25 of the 720 managers we trackUSD 188m2.7%
13 Nasdaq: ORKAHeld by 33 of the 720 managers we trackUSD 183m2.7%
14 Nasdaq: ALMSHeld by 29 of the 720 managers we trackUSD 179m2.6%
15 Nasdaq: IONSHeld by 44 of the 720 managers we trackUSD 174m2.5%
Guardant Health, Inc.: 7.4%Immunovant, Inc.: 5.2%Structure Therapeutics Inc.: 3.7%Vaxcyte, Inc.: 3.6%Alnylam Pharmaceuticals, Inc.: 3.6%Veradermics, Inc: 3.6%Tarsus Pharmaceuticals, Inc.: 3.4%Nuvalent Inc: 3.2%Positions 9 to 15: 19.2%The rest of the book: 47.1%67POSITIONS
How the book is split
  • Guardant Health, Inc.7.4%
  • Immunovant, Inc.5.2%
  • Structure Therapeutics Inc.3.7%
  • Vaxcyte, Inc.3.6%
  • Alnylam Pharmaceuticals, Inc.3.6%
  • Veradermics, Inc3.6%
  • Tarsus Pharmaceuticals, Inc.3.4%
  • Nuvalent Inc3.2%
  • Positions 9 to 1519.2%
  • The rest of the book47.1%
Next: returns year by year
Returns year by year

Ahead of the S&P 500 in 2025, even at the low end of our range

The SEC filings of Deep Track Biotechnology Master Fund carry no return figures. These are our estimates, each with the range we think the true figure falls in and a grade for how it was reached.

Gold bars are the fund. The thin line on each bar is the range we think the true figure falls in. Grey bars are the S&P 500 total return in U.S. dollars, dividends reinvested, over the same calendar years. It is there as a picture of the market, not as the benchmark this fund sets itself.

-20%0%20%40%60%80%20224.5%20237.5%202410.3%202548.4%2026 to date16.3%
PeriodReturnLikely rangeGradeS&P 500Difference
20224.5%-19.4% to 28.5%D-13F-18.1%+22.7 pts
20237.5%-15.9% to 30.8%D-13F26.3%-18.8 pts
202410.3%-13.0% to 33.7%D-13F25.0%-14.7 pts
202548.4%19.0% to 77.7%D-13F17.9%+30.5 pts
2026 to 30 Jun16.3%-6.9% to 39.6%D-13F

The estimate is built from the manager's whole 13F long book. We attach it to this fund as the largest hedge fund Deep Track Capital, LP runs.

Returns are before the fees an investor pays unless they come from a public holder's reported value, which is after the fund's own fees.

USD 100 in Deep Track Biotechnology Master Fund against the S&P 500start of 2022 = 100

The gold line compounds our yearly figures. The shaded area is where the line would run if every year came in at the low or the high end of its range. The grey line is the S&P 500 with dividends.

100200300400StartEnd 2022End 2023End 2024End 2025Fund 184S&P 500 152

By the end of 2025, USD 100 in the fund had become about USD 184 by our estimate, against USD 152 in the index.

What an investor would have kept, 2022 to 2025

Takes our yearly figures for Deep Track Biotechnology Master Fund and shows what is left after fees and tax, next to the same money inside a PPLI policy. Change any of the numbers. Our 13F-based figures price the manager's long book and take no fees off, so the tool treats them as before fees. Public filings do not settle that, and they do not give the fund's terms either. The fees are yours to set; put both at 0 to read the estimate as if it were already after fees.

Deep Track Biotechnology Master Fund, as estimatedour yearly figures compounded, before fees and taxUSD 1.8m
After the fund's feeswith the fees you entered, charged above a high-water markUSD 1.6m
After tax, held directlygains taxed every year at the rate you enteredUSD 1.3m
Held inside a PPLI policyno yearly tax on gains inside a policy that keeps to the rules, less the yearly policy costUSD 1.5m
S&P 500 with dividendsthe index over the same years, before taxUSD 1.5m
Each year: as estimated, after fees, after tax and inside a policy
YearAs estimatedAfter feesAfter taxInside a policyS&P 500
20224.5%2.4%1.4%1.4%-18.1%
20237.5%4.8%2.8%3.7%26.3%
202410.3%7.1%4.2%6.0%25.0%
202548.4%37.5%22.2%36.1%17.9%

The fee defaults of 1.5% and 20% are common hedge fund terms, not this fund's. The tax rate of 40.8% is the top U.S. federal rate on short-term gains with the net investment income tax; a fund whose gains are mostly long-term would be taxed at 23.8%. State tax is not included. Policy costs differ by carrier and by the size of the policy. If every year had come in at the bottom or the top of our range, the first line would read USD 702,000 or USD 4m. An illustration, not advice.

The record in numbers

Worked out from the yearly figures above, 2022 to 2025. They carry the same ranges and grades.

Annualised return16.5%
Best year48.4% in 2025
Worst year4.5% in 2022
Years ahead of the S&P 5002 of 4
Total over the period83.9%
S&P 500 over the period52.4%
Losing years0 of 4
Average width of our range50 points
Returns by period

Annualised where the period is longer than a year. The range compounds the low and high ends of each year.

PeriodDeep Track Biotechnology Master FundLikely rangeS&P 500Difference
Latest year202548.4%19.0% to 77.7%17.9%+30.5 pts
Three years, a year2023 to 202520.7%-4.5% to 45.9%23.0%-2.3 pts
Risk, as far as yearly figures show it

Measured at year ends only. A fall and recovery inside a single year does not appear here.

Deepest fall between year endsNone
S&P 500, same measure-18.1%
Losing years0 of 4
2022, side by side
Deep Track Biotechnology Master Fund4.5%range -19.4% to 28.5%
S&P 500-18.1%with dividends

2022 was the one year in this period when the index fell. By our estimate the fund made money.

Compare with other funds

Type the name of any fund we estimate and it joins the table. Up to five at a time. Every figure is an estimate; open a fund to see its range and grade.

Fund20212022202320242025
Deep Track Biotechnology Master Fund4.5%7.5%10.3%48.4%
S&P 500 with dividends28.7%-18.1%26.3%25.0%17.9%

Over 2023 to 2025 the estimates compound to 75.9%, or 20.7% a year.

Next: where the numbers come from
Where the numbers come from

Built from the manager's quarterly 13F filings

A hedge fund reports almost nothing about itself. Others report about it, and that is what we read.

Deep Track Capital, LP's disclosed U.S. long book

Every quarter the manager lists its U.S. listed long positions on Form 13F, most recently USD 6.9bn with options counted at the value of the shares they cover for 30 June 2026. Pricing those positions through each year gives the return of the long book alone. It covers all the manager's clients, not this fund, and leaves out shorts, leverage, non-U.S. holdings and fees. The long book is most of what the manager's hedge funds hold, so it says a good deal about this fund.

2022202320242025
13F long book-7.9%7.9%-3.6%71.5%
S&P 500-18.1%26.3%25.0%17.9%
-20%0%20%40%60%80%2022202320242025
Next: size and investors
Size and investors

USD 5.1bn in gross assets, up from USD 1.1bn reported in 2021

The fund in Form ADV, Schedule D

What the adviser reported about this fund in the filing of 28 March 2024. Gross assets are the fund's total assets before borrowings are deducted. They are not net assets and say nothing about performance.

Gross asset valueUSD 5.1bn
Minimum investmentUSD 5m
Beneficial owners134
Owned by the adviser and its people5%
Owned by funds of funds15%
Owned by non-U.S. persons11%
Investor eligibility3(c)(7): qualified purchasers
DomicileCayman Islands
StructureMaster fund
Full legal nameDeep Track Biotechnology Master Fund, Ltd.
SEC private fund ID805-8843084347
Gross assets over timeUSD bn, by the year the figure was filed

Each bar is the gross asset value in that year's Form ADV. An annual filing reports the previous fiscal year end, so each bar describes the year before. A change in gross assets is not a return: money coming in, money going out, borrowing and performance all move it, and the filings do not say which.

20211.120221.820233.720245.1
Master and feeder funds

Investors often enter through a feeder that passes their money to a master fund, where the trading happens.

  • Feeder: Deep Track Biotechnology Offshore Fund, Ltd.
  • Feeder: Deep Track Biotechnology Fund, LP
Next: who audits and administers it
Service providers

Audited by Ernst & Young LLP, administered by Morgan Stanley Fund Services USA

An outside auditor and an administrator that is not part of the manager are the two checks an investor can verify from public filings.

Named by the adviser in Form ADV Schedule D, questions 23 to 28, in the filing of 28 March 2024.

RoleFirmWhereAs stated in the filing
AuditorErnst & Young LLPNew York, New YorkIndependent, pcaob registered
AuditorErnst & Young Ltd.George Town, Cayman IslandsIndependent, pcaob registered
AdministratorMorgan Stanley Fund Services USA LLCPurchase, New YorkNot related to the adviser
AdministratorMorgan Stanley Fund Services (Cayman) Ltd.Grand Cayman, Cayman IslandsNot related to the adviser
Prime brokerUBS Securities LLCNew York, New YorkAlso custodian
Prime brokerJ.P. Morgan Prime Inc.New York, New YorkAlso custodian
Prime brokerMorgan Stanley & Co. LLCNew York, New YorkAlso custodian
CustodianJ.P. Morgan Prime Inc.New York, New YorkNot related to the adviser
CustodianThe Northern Trust International Banking CorporationJersey City, New JerseyNot related to the adviser
CustodianMorgan Stanley & Co. LLCNew York, New YorkNot related to the adviser
CustodianUBS Securities LLCNew York, New YorkNot related to the adviser
Audit and valuation
Audited every yearYes
Statements under U.S. GAAPYes
Audited statements sent to investorsYes
Share of assets valued by an outside party92%
General partner, manager or directors

Form ADV Schedule D, question 3.

  • Julie O'Hara (Director)
  • David Kroin (Director)
  • Matt Auriemma (Director)
Next: how the fund is offered
The offering, from Form D

Offering filed by a related vehicle

The Form D linked to this fund was filed by Deep Track Biotechnology Fund, LP, a related vehicle of the same manager, often the feeder or offshore twin through which investors come in. The figures below describe that vehicle.

Issuer on the filingDeep Track Biotechnology Fund, LP
Total sold to dateUSD 842m
Investors to date44
Date of first sale1 April 2021
Exemptions claimed06b, 3C, 3C.7
EntityLimited Partnership
JurisdictionDelaware
Latest filingD/A, 1 April 2026
Form D filings on EDGAR6
Next: the manager
The manager

Run by Deep Track Capital

AdviserDeep Track Capital, LP
StatusSEC-registered adviser
Registered since12 March 2021
SEC number801-120500
CRD number312459
OfficeGreenwich, CT
Latest Form ADV31 March 2026
Brochure (Part 2A)31 March 2026
In the manager's own words

What Deep Track Capital, LP says about itself on deeptrackcapital.com, read on 14 November 2026. A sentence in quotation marks is the firm's own; the rest is in our words. These are the firm's statements, not ours, and we have not checked them. They describe the firm as a whole, not this fund.

“Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry.”

Offices it listsGreenwich
People namedDavid Kroin, Founder, Chief Investment Officer
Brett Erkman, Managing Director
Rebecca Luse, Managing Director
On the siteA team page
The manager at a glance

Gross assets are added across the funds we cover and count a master fund and its feeders separately, so they overstate the money the firm runs.

Funds of this manager on PPLI.com1
Their gross assets togetherUSD 5.1bn
With return figures1
U.S. long book on Form 13FUSD 6.9bn
Positions in that book67
Form ADV filings that list this fund4
The paper trail

Dates taken from the filings themselves.

  • 12 Mar 2021 Deep Track Capital, LP registered with the SEC
  • 8 Jul 2021 First Form ADV in the SEC's bulk data to list the fund
  • 28 Mar 2024 Latest Form ADV listing the fund in the bulk data
  • 31 Mar 2026 Latest Form ADV of the manager
  • 1 Apr 2026 Latest Form D of the related vehicle
  • 14 Aug 2026 Latest Form 13F of the manager, for 30 June 2026
Next: holding it inside a policy
Inside a policy

Can Deep Track Biotechnology Master Fund be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. U.S. tax rules test what a policy holds for diversification, and a fund that is also sold to investors outside insurance accounts counts as a single holding and is not looked through to what it owns. Choosing such a fund yourself also raises the investor-control question the IRS has ruled on.

In practice a U.S.-compliant policy reaches a hedge fund strategy through an insurance-dedicated fund, whose interests are held by insurers' separate accounts with a few exceptions the regulations allow, or through a separately managed account run for the insurer. Policies issued outside the United States for people who are not U.S. taxpayers follow the rules of their own jurisdiction, and those differ.

Some managers run an insurance-dedicated version of their strategy. Where they do, gains that a taxable investor would pay tax on each year can build up inside the policy, as long as the policy keeps to the rules. We have no record that Deep Track Capital, LP offers one. That is a gap in our file, not a finding that it does not. We keep a directory of insurance-dedicated funds and the managers behind them.

Insurance-dedicated funds on PPLI.com   Hedge fund strategies inside PPLI

The diversification test, on the manager's reported book

The investments inside a policy must be spread: no more than 55% in one holding, 70% in two, 80% in three and 90% in four. This table runs that test on the positions Deep Track Capital, LP reported on Form 13F for 30 June 2026. It is a rough guide only, since an insurance-dedicated version would hold the whole strategy, shorts included.

MeasureLimitThis bookResult
The largest holding55%7%Within the limit
The two largest70%13%Within the limit
The three largest80%16%Within the limit
The four largest90%20%Within the limit

On this evidence the long book is spread widely enough.

Next: notes on this file
Notes

What the filings leave open

What we would ask the manager

Questions the filings raise and cannot answer.

  • 92% of the assets are valued by an outside party. Who values the rest, and how often is that tested?
  • Our estimate rests on your long book alone. What did the short book, leverage and trading inside the quarter add or take away?
  • Do you offer this strategy as an insurance-dedicated fund or a separately managed account for insurers?
Changes to this file
  • 13 Nov 2026 File opened from SEC filings
  • 14 Nov 2026 Manager's website read and its facts added
  • 15 Nov 2026 Page revised.
The manager's response

Not yet received. Deep Track Capital, LP can ask us to check any fact on this page and can send a response, which we will publish here unedited. Write to the editor.

Next: questions
Questions

Questions about Deep Track Biotechnology Master Fund

What has Deep Track Biotechnology Master Fund returned?

The SEC filings of Deep Track Biotechnology Master Fund carry no return figures. PPLI Vortex estimates, from SEC filings: 7.5% in 2023, 10.3% in 2024, 48.4% in 2025, 16.3% in 2026 to 30 Jun. Each estimate has a range; for 2025 it is 19.0% to 77.7%.

How reliable are the return figures for Deep Track Biotechnology Master Fund?

They are estimates, not figures reported by the fund. Each one is shown with a range and a grade. The grade for the latest figure is D-13F: estimated from the manager's Form 13F long book. Shorts, leverage, trading within a quarter and fees are not visible in public filings.

What does Deep Track Biotechnology Master Fund invest in?

Deep Track Biotechnology Master Fund does not publish its holdings. Its manager, Deep Track Capital, LP, reported 67 U.S.-listed positions worth USD 6.9bn on Form 13F for 30 June 2026. The largest were Guardant Health, Inc., Immunovant, Inc., Structure Therapeutics Inc. The filing covers all of the manager's accounts and excludes short positions.

How big is Deep Track Biotechnology Master Fund?

Deep Track Biotechnology Master Fund reported gross assets of USD 5.1bn in the Form ADV filed 28 March 2024. Gross assets are total assets before borrowings are deducted, so the figure is larger than what investors have put in when the fund uses leverage.

What is the minimum investment in Deep Track Biotechnology Master Fund?

USD 5m, as stated in Form ADV Schedule D. The fund relies on the 3(c)(7) exclusion, so investors must be qualified purchasers. Managers can and do waive minimums.

Who audits and administers Deep Track Biotechnology Master Fund?

The auditor is Ernst & Young LLP. The administrator is Morgan Stanley Fund Services USA LLC. These are the firms named in the Form ADV filed 28 March 2024.

Who runs Deep Track Capital, LP?

On its own website Deep Track Capital, LP names David Kroin (Founder, Chief Investment Officer), Brett Erkman (Managing Director) and Rebecca Luse (Managing Director). That is the list the firm gave when we read the site on 14 November 2026, and people move, so check with the firm.

How do I contact Deep Track Capital, LP?

The firm can be reached by email at [email protected], the details it gives on deeptrackcapital.com. PPLI.com is not connected to the firm and cannot pass messages on.

Where is Deep Track Capital, LP based?

Its website lists Greenwich. The address on its SEC filing is in the manager section above.

Who manages Deep Track Biotechnology Master Fund?

Deep Track Capital, LP, CRD number 312459. It is an SEC-registered adviser.

Can Deep Track Biotechnology Master Fund be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. Under U.S. tax rules a policy reaches a hedge fund strategy through an insurance-dedicated fund or a separately managed account run for the insurer, not through a fund that is also sold to other investors. Policies issued outside the United States follow their own rules. We have no record that Deep Track Capital, LP offers an insurance-dedicated version, so an investor would need to ask the firm.

What did Deep Track Biotechnology Master Fund return each quarter?

Deep Track Biotechnology Master Fund does not file quarterly returns with the SEC. PPLI Vortex estimates 19.3% in the third quarter of 2025, 22.8% in the fourth quarter of 2025, 0.9% in the first quarter of 2026 and 15.7% in the second quarter of 2026. Each figure has a range, shown on the page.

Next: how we work
Method and sources

How this page was put together

The return figures on this page come from PPLI Vortex, the engine we built to work out hedge fund returns from SEC filings. For this fund it takes the long positions the manager reports each quarter on Form 13F, prices them through the following quarter, and scales the result to how hedge funds with a similar footprint have behaved, using publicly reported returns as calibration. It is not the return the fund reports to its investors, which also reflects shorts, derivatives, cash, trading within the quarter and fees. Fund facts come from Form ADV Schedule D, section 7.B.(1), and from Form D. Apart from the short passage taken from the manager's public website and marked as such, nothing here comes from the fund or its manager.

Form ADV usedFiled 28 March 2024
Form D used1 April 2026
13F quarter30 June 2026
EnginePPLI Vortex v12.4
CorrectionsWrite to the editor

The full methodology

For the fund and its manager

Do you run Deep Track Biotechnology Master Fund? Help us get it right.

If you manage this fund or work for Deep Track Capital, LP, you can correct a fact, send us figures we do not have, such as audited returns, fees and terms, or point out a mistake. So can anyone else who spots one.

[email protected]

Please give the fund's name and its SEC private fund ID, 805-8843084347. We check what we receive against the filings, mark on the page what came from the manager, and publish any response you send, unedited.

Important information

Return figures on this page are estimates computed by PPLI.com from public regulatory filings using its PPLI Vortex engine. They are not reported, confirmed or audited by the fund, each is shown with a range and a confidence grade, and the true figures may differ materially from what investors received.

PPLI.com has no relationship with Deep Track Biotechnology Master Fund or Deep Track Capital, LP, and neither has reviewed or approved this page. Facts are taken from filings with the U.S. Securities and Exchange Commission as of the dates shown and may since have changed. Holdings come from the manager's Form 13F, which covers all of its accounts and omits short positions, so they are not a statement of what this fund owns.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy an interest in any fund or insurance policy. Interests in private funds are offered only to eligible investors, by the fund's own offering documents. Past performance, estimated or reported, does not predict future results. The calculators are illustrations built on assumptions you can change. To report an error, write to the editor.

Full legal name Deep Track Biotechnology Master Fund, Ltd.SEC private fund ID 805-8843084347Updated 15 November 2026
Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.